References
- World Health Organization. Rolling updates on coronavirus disease (COVID-19). Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [last accessed 3 June 2020].
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, China Medical Treatment Expert Group for Covid-19, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382(18):1708–1720. doi:https://doi.org/10.1056/NEJMoa2002032.
- Tian J, Miao X. Challenges and recommendations for cancer care in the COVID-19 pandemic. doi:https://doi.org/10.20892/j.issn.2095-3941.2020.0300
- Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev 2020;36(7):e3319. doi:https://doi.org/10.1002/dmrr.3319.
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:https://doi.org/10.1016/S0140-6736(20)30566-3.
- Bousquet J, Mantzouranis E, Cruz AA, Ait-Khaled N, Baena-Cagnani CE, Bleecker ER, Brightling CE, Burney P, Bush A, Busse WW, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010;126(5):926–938. doi:https://doi.org/10.1016/j.jaci.2010.07.019.
- Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, Shi J, Zhou M, Wu B, Yang Z, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;146(1):110–118. doi:https://doi.org/10.1016/j.jaci.2020.04.006.
- Huang K, Yang T, Xu J, Yang L, Zhao J, Zhang X, Bai C, Kang J, Ran P, Shen H, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet 2019;394(10196):407–418. doi:https://doi.org/10.1016/S0140-6736(19)31147-X.
- Janson C, Chinn S, Jarvis D, Burney P. Physician-diagnosed asthma and drug utilization in the European Community Respiratory Health Survey. Eur Respiratory J 1997;10(8):1795–1802. doi:https://doi.org/10.1183/09031936.97.10081795.
- Holgate ST, Wenzel S, Postma DS, Weiss ST, Renz H, Sly PD. Asthma. Nat Rev Dis Primers 2015;1:15025 doi:https://doi.org/10.1038/nrdp.2015.25.
- WHO/International Severe Acute Respiratory and Emerging Infection. Consortium case record form for severe acute respiratory infections. Available from: https://media.tghn.org/medialibrary/2016/06/ISARIC-WHO-SARI_Case_Record_Form_7JAN16.pdf [last accessed 3 June 2020].
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:https://doi.org/10.1016/S0140-6736(20)30183-5.
- National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Available from: http://www.nhlbi.nih.gov/ [last accessed 3 June 2020].
- World Health Organization. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim guidance. Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected [last accessed 3 June 2020].
- National Health Commission of the People’s Republic of China. 2020. Chinese management guideline for COVID-19 (version 7.0, in Chinese) [last accessed 3 March 2020].
- Wilson GB, Fudenberg HH. Ciliary dyskinesia factors in cystic fibrosis and asthma . Nature 1977;266(5601):463–464. doi:https://doi.org/10.1038/266463a0.
- Amin K. The role of the T lymphocytes and remodeling in asthma. Inflammation 2016;39(4):1475–1482. doi:https://doi.org/10.1007/s10753-016-0380-9.
- Okada S, Hasegawa S, Hasegawa H, Ainai A, Atsuta R, Ikemoto K, Sasaki K, Toda S, Shirabe K, Takahara M, et al. Analysis of bronchoalveolar lavage fluid in a mouse model of bronchial asthma and H1N1 2009 infection. Cytokine 2013;63(2):194–200. doi:https://doi.org/10.1016/j.cyto.2013.04.035.
- Fujimoto Y, Hasegawa S, Matsushige T, Wakiguchi H, Nakamura T, Hasegawa H, Nakajima N, Ainai A, Oga A, Itoh H, et al. Pulmonary inflammation and cytokine dynamics of bronchoalveolar lavage fluid from a mouse model of bronchial asthma during A(H1N1)pdm09 influenza infection. Sci Rep 2017;7(1):9128. doi:https://doi.org/10.1038/s41598-017-08030-w.
- Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020;135(23):2033–2040. doi:https://doi.org/10.1182/blood.2020006000.
- Mortensen E, Louie J, Pertowski C, Cadwell BL, Weiss E, Acosta M, Matyas BT. Epidemiology and outcomes of adults with asthma who were hospitalized or died with 2009 pandemic influenza A (H1N1) – California, 2009. Influenza Other Respi Viruses 2013;7(6):1343–1349. doi:https://doi.org/10.1111/irv.12120.
- Mahdavinia M, Foster KJ, Jauregui E, Moore D, Adnan D, Andy-Nweye AAB, Khan S, Bishehsari F. Asthma prolongs intubation in COVID-19. J Allergy Clin Immunol 2020;8:2388–2391. doi:https://doi.org/10.1016/j.jaip.2020.05.006.
- Liu X, Zhou H, Zhou Y, Wu X, Zhao Y, Lu Y, Tan W, Yuan M, Ding X, Zou J, et al. Risk factors associated with disease severity and length of hospital stay in COVID-19 patients. J Infect 2020;81(1):e95–e97. doi:https://doi.org/10.1016/j.jinf.2020.04.008.
- Hou W, Zhang W, Jin R, Liang L, Xu B, Hu Z. Risk factors for disease progression in hospitalized patients with COVID-19: a retrospective cohort study. Infect Dis (London, England) 2020:1–8. doi:https://doi.org/10.1080/23744235.2020.1759817.
- Zhang JJY, Lee KS, Ang LW, Leo YS, Young BE. Risk factors of severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis and meta-regression analysis. Clin Infect Dis 2020. doi:https://doi.org/10.1093/cid/ciaa576.
- Hu L, Chen S, Fu Y, Gao Z, Long H, Wang J-M, Ren H-W, Zuo Y, Li H, Wang J, et al. Risk factors associated with clinical outcomes in 323 COVID-19 hospitalized patients in Wuhan, China. Clin Infect Dis 2020;52(7):498–505. doi:https://doi.org/10.1093/cid/ciaa539.
- Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, Li Q, Jiang C, Zhou Y, Liu S, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect 2020;81(2):e16–e25. doi:https://doi.org/10.1016/j.jinf.2020.04.021.
- Wei Y-Y, Wang R-R, Zhang D-W, Tu Y-H, Chen C-S, Ji S, Li C-X, Li X-Y, Zhou M-X, Cao W-S, et al. Risk factors for severe COVID-19: evidence from 167 hospitalized patients in Anhui, China. J Infect 2020;81(1):e89–e92. doi:https://doi.org/10.1016/j.jinf.2020.04.010.
- Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. Respirat Med 2017;5:691–706.
- Wang L, Foer D, Bates DW, Boyce JA, Zhou L. Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19. J Allergy Clin Immunol 2020;146:808–812. doi:https://doi.org/10.1016/j.jaci.2020.07.018.
- Heffler E, Detoraki A, Contoli M, Papi A, Paoletti G, Malipiero G, Brussino L, Crimi C, Morrone D, Padovani M, et al. COVID-19 in Severe Asthma Network in Italy (SANI) patients: clinical features, impact of comorbidities and treatments. Allergy 2020. doi:https://doi.org/10.1111/all.14532.
- Grandbastien M, Piotin A, Godet J, Abessolo-Amougou I, Ederlé C, Enache I, Fraisse P, Tu Hoang TC, Kassegne L, Labani A, et al. SARS-CoV-2 pneumonia in hospitalized asthmatic patients did not induce severe exacerbation. J Allergy Clin Immunol Pract 2020;8(8):2600–2607. doi:https://doi.org/10.1016/j.jaip.2020.06.032.
- Beurnier A, Jutant EM, Jevnikar M, Boucly A, Pichon J, Preda M, Frank M, Laurent J, Richard C, Monnet X, et al. Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. Eur Respir J 2020;56(5):2001875. doi:https://doi.org/10.1183/13993003.01875-2020.
- Simpson JL, Carroll M, Yang IA, Reynolds PN, Hodge S, James AL, Gibson PG, Upham JW. Reduced antiviral interferon production in poorly controlled asthma is associated with neutrophilic inflammation and high-dose inhaled corticosteroids. Chest 2016;149(3):704–713. doi:https://doi.org/10.1016/j.chest.2015.12.018.
- Southworth T, Pattwell C, Khan N, Mowbray SF, Strieter RM, Erpenbeck VJ, Singh D. Increased type 2 inflammation post rhinovirus infection in patients with moderate asthma. Cytokine 2020;125:154857 doi:https://doi.org/10.1016/j.cyto.2019.154857.